Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View AYTU insider activity ↗

AYTUAYTU BIOPHARMA, INC

THE LATEST REPORTED YEAR

The company reported a loss.

$14.25M net loss for the year ended June 30, 2026. These are reported results, not a forecast or a stock recommendation.

Revenue$57.57MYear ended June 30, 2026
Profit or loss-$14.25MYear ended June 30, 2026
Cash from the business$3.28MYear ended June 30, 2026
Total assets$105.01MAs of June 30, 2026
Total liabilities$100.72MAs of September 30, 2023
Cash & equivalents$26.31MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$27.63M
2020-06
$65.63M
2021-06
$96.67M
2022-06
$107.4M
2023-06
$65.18M
2024-06
$66.38M
2025-06
$57.57M
2026-06

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
July 1, 2025 – June 30, 2026$57,570,000September 22, 202610-K ↗
July 1, 2024 – June 30, 2025$66,382,000September 22, 202610-K ↗
July 1, 2023 – June 30, 2024$65,183,000September 23, 202510-K ↗
July 1, 2022 – June 30, 2023$107,399,000September 26, 202410-K ↗
July 1, 2021 – June 30, 2022$96,669,000October 12, 202310-K ↗
July 1, 2020 – June 30, 2021$65,632,000September 27, 202210-K ↗
July 1, 2019 – June 30, 2020$27,632,000September 28, 202110-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 11, 2026

Response SHA-256: e5e982009b4d90ada747a0c64313570ad4bfb7a071eb6e975bd00bbd25996f68

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.